Why did the stock price of the leading company get the orphan drug identification?

Event: Recently, GRCL.

Why did the market react to the ups and downs of Genxi's product?

01 Bringing hope to patients who have not met their clinical needs

Multiple myeloma is still a problem that the medical community has not found the best solution

The drug has not yet been declared in China, but the FIC Intelligence database of Zhongkang shows that 3 international clinical registration numbers indicate that GC012F is conducting multi-center, phase I clinical trials initiated by investigators in China, including new cases of multiple myeloma And clinical trials in high-risk patients

Source: Zhongkang FIC Intelligence database

Prior to this, Genxi Biosciences has announced the latest clinical research progress of GC012F in the treatment of relapsed/refractory multiple myeloma at a number of top international academic conferences

02 Proprietary technology shortens production time and reduces costs

Conventional autologous CAR-T cell therapy takes a long time to prepare and is difficult to produce on a large scale, resulting in high prices and poor patient accessibility

The company's other general-purpose CAR-T technology that can achieve large-scale production is also the industry's research and development trend.

03 There is not much market space imaginable in the future

Approximately 160,000 patients are diagnosed with multiple myeloma every year, among which high-risk patients account for 20%-30%.

And Genxi Bio, which was established in 2017, was listed on the US stock market in January this year, and no commercial product has been launched yet

Source: Company's official website

04 Conclusion

Genxi Bio’s product pipeline has disclosed 5 CAR-T product therapies.

Zhongkang FIC Intelligence is an analytical database that assists companies in making varieties improvement and innovation decisions